3Lim PohLian. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network[J]. Vaccine, 2010,28 (46) : 7389- 7395.
4Ninove L, Tan C, Nougairede A, et al. Impact of diag- nostic procedures on patient management and hospitali- zation cost during the 2000 and 2005 enterovirus epi- demics in Marseilles, France[J]. Clin Microbiol Infect, 2010,16 (6) : 651-656.
5Jian ZJ. Etiology and diagnosis of heart failure in theelderly patients. Chin J Geriatr, 2005, 2:156-158.
6Weber M, Hamm C. Role of B-type natriuretie peptide (BNP) and NT proBNP in clinical routine. Heart, 2006, 92:843-849.
7D'Aloia A,Faggiano P, Aurigemma G, et al. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coil Cardiol, 2003, 41:1805-1811.
8Chen HH, Bumett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curt Cardiol Rep, 2000, 2:198-205.
9McCullough PA, Nowak RM, McCord J, et al. B- type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. Circulation, 2002, 106:416-422.
10Nagele H, Bahlo M,KlapdorR, etal. CA125 and its relation to cardiac function. Am Heart J, 1999, 137: 1044-1045.
